<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04842617</url>
  </required_header>
  <id_info>
    <org_study_id>SHR6390-III-303</org_study_id>
    <nct_id>NCT04842617</nct_id>
  </id_info>
  <brief_title>Phase III Study ：SHR6390/Placebo Combined With Endocrine Therapy for the Adjuvant Treatment of Hormone Receptor Positive,Human Epidermal Receptor 2 Negative</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind Phase III Study：SHR6390/Placebo Combined With Endocrine Therapy for the Adjuvant Treatment of Hormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stage，Female Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is to evaluate the efficacy and safety of SHR6390 combined with endocrine therapy&#xD;
      for the adjuvant treatment of hormone receptor positive,Human Epidermal Receptor 2 negative.&#xD;
&#xD;
      To observe the PK characteristics of SHR6390 combined with endocrine therapy for the adjuvant&#xD;
      treatment of hormone receptor positive,Human Epidermal Receptor 2 negative.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">April 30, 2021</start_date>
  <completion_date type="Anticipated">October 31, 2031</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2026</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>SHR6390 Tablets compared with placebo</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>IDFS（Invasive Disease-Free Survival）</measure>
    <time_frame>at least 5 years from the date of randomization .</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>DFS(Disease-Free Survival)</measure>
    <time_frame>The observation time is at least 5 years from the date of randomization . Evaluations were conducted every 26 weeks for the first 2 years and every 52 weeks thereafter, with a follow-up of at least 5 years.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS(Overall Survival)</measure>
    <time_frame>up to approximately 5 years.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DDFS(Distant Disease-Free Survival)</measure>
    <time_frame>from randomization to distant recurrence or death from any cause, whichever occurs first. Evaluations were conducted every 26 weeks for the first 2 years and every 52 weeks thereafter, with a follow-up of at least 5 years.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With adverse events (AEs) and serious adverse events (SAEs) Incidence, nature, and severity of adverse events graded according to the NCI CTCAE v5.0.</measure>
    <time_frame>up to approximately 5 years</time_frame>
    <description>To evaluate the safety and tolerability of SHR6390 combined with endocrine therapy for the adjuvant treatment of hormone receptor positive,Human Epidermal Receptor 2 negative female breast cancer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of SHR6390 will be analyzed for PK samples</measure>
    <time_frame>collected on day 1 of the 5th, 9th, 13th and 17th weeks, respectively.</time_frame>
    <description>To explore the PK characteristics of SHR6390 combined with endocrine therapy for the adjuvant treatment of hormone receptor positive,Human Epidermal Receptor 2 negative female breast cancer.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">4350</enrollment>
  <condition>Hormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stage，Female Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment group B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR6390</intervention_name>
    <description>SHR6390 combined with endocrine therapy</description>
    <arm_group_label>Treatment group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo combined with endocrine therapy</description>
    <arm_group_label>Treatment group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Postmenopausal or premenopausal/perimenopausal female patients aged ≥18 years and ≤75&#xD;
             years old.&#xD;
&#xD;
          2. Pathological examination diagnosed as invasive breast cancer with HR+ and HER2-.&#xD;
&#xD;
          3. Underwent radical resection of breast cancer.&#xD;
&#xD;
          4. The score of ECOG was 0 - 1.&#xD;
&#xD;
          5. Fertile women must have a negative serum pregnancy test within 7 days before&#xD;
             randomization, and be willing to use acceptable non hormonal contraceptive measures.&#xD;
&#xD;
          6. With my consent and informed consent, I am willing and able to comply with the planned&#xD;
             visit, study treatment plan, laboratory examination and other test procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. This Pathological examination diagnosed as HER2-positive breast cancer.&#xD;
&#xD;
          2. The history of any malignant tumor other than breast cancer within 5 years before&#xD;
             randomization.&#xD;
&#xD;
          3. At the same time participate in other anti-tumor therapy clinical trials (including&#xD;
             endocrine therapy or immunotherapy, etc.).&#xD;
&#xD;
          4. In the 6 months before randomization, the following conditions occurred: myocardial&#xD;
             infarction, severe/unstable angina pectoris, , etc&#xD;
&#xD;
          5. Inability to swallow, intestinal obstruction, or other factors that affect the&#xD;
             administration and absorption of the drug.&#xD;
&#xD;
          6. There are other serious physical or mental illnesses or laboratory abnormalities that&#xD;
             may increase the risk of participating in the study, or interfere with the results of&#xD;
             the study, as well as patients who the investigator believes are not suitable for&#xD;
             participating in this study.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 30, 2021</study_first_submitted>
  <study_first_submitted_qc>April 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2021</study_first_posted>
  <last_update_submitted>May 20, 2021</last_update_submitted>
  <last_update_submitted_qc>May 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

